Abstract:Antibody-mediated rejection (AMR) is the main barrier to renal graft survival, and mouse renal AMR models are important to study this process. Current mouse models are established by priming the recipient to donor skin for over 7 days before kidney transplantation. The robustness of AMR in these cases is too strong to mimic clinical AMR and it is unclear why altering the priming times ranging from 7 to 91 days fails to reduce the AMR potency in these models. In the present study, we found that the donor-recipient combination and skin graft size were determinants of donor-specific antibody (DSA) development patterns after skin transplantation. DSA-IgG was sustained for over 100 days after skin challenge, accounting for an identical AMR robustness upon different skin priming times over 7 days. However, decreasing the skin priming time within 7 days attenuated the robustness of subsequent renal allograft AMR in C3H to Balb/c mice. Four-day skin priming guaranteed that recipients develop acute renal AMR mixed with a high ratio of graft-infiltrating macrophages, renal grafts survived for a mean of 6.4 ± 2.1 days, characterized by typical AMR histological changes, such as glomerulitis, peritubular capillary (PTC) dilation, and capillaritis, deposition of IgG and C3d in PTCs, but less prevalence of microthrombus, whereas the cellular rejection histological change of tubulitis was absent to mild. With this scheme, we also found that the renal AMR model can be developed using common mouse strains such as C57BL/6 and Balb/c, with mean prolonged renal graft survival times of 14.4 ± 5.0 days. Finally, we proved that donor-matched skin challenge after kidney transplantation did not strongly affect DSA development and kidney graft outcome. These findings may facilitate an understanding and establishment of mouse renal allograft AMR models and promote AMR-associated studies.

Rats and mice immunised with chimeric human/mouse proteinase 3 produce autoantibodies to mouse Pr3 and rat granulocytes

Mouse Model Established by Early Renal Transplantation after Skin Allograft Sensitization Mimics Clinical Antibody-Mediated Rejection.

Construction, Expression, and Characterization of a Novel Human-Mouse Chimeric Antibody, Hm3A4: A Potential Therapeutic Agent for B and Myeloid Lineage Leukemias.

Generation and Identification of Phage Engineering Antibodies Library Against Hamster Prion Protein

Introduction of a novel chimeric active immunization mouse model of PLA2R1-associated membranous nephropathy

Establishment of Hamster- and Human-Prnp Transgenic Mice.

Human Anti-prion Antibodies Block Prion Peptide Fibril Formation and Neurotoxicity

Epitope Mapping of Human α3(IV)NC1-Induced Membranous Nephropathy in Mice

Proteinase 3 Interferes With C1q-Mediated Clearance of Apoptotic Cells

Rat antibodies bearing idiotypes of mouse antibodies against bromelain-treated mouse RBC

Preparation of Monoclonal Antibodies Against Prion Proteins with Full-Length Hamster PrP.

The role of type 3 muscarinic acetylcholine receptor polypeptide in the pathogenesis of Sj(o)gren's syndrome

Proteinase 3, the Autoantigen in Granulomatosis with Polyangiitis, Associates with Calreticulin on Apoptotic Neutrophils, Impairs Macrophage Phagocytosis, and Promotes Inflammation

Murine Monoclonal Antibodies Generated Against Mouse/Rat Hemokinin-1

Rat models as tool to develop new immunotherapies.

Relapsing polychondritis, induced in mice with matrilin 1, is an antibody- and complement-dependent disease.

Development of a C3 Humanized Rat as a New Model for Evaluating Novel C3 Inhibitors

Development of a Neutralizing Mouse-Pig Chimeric Antibody with Therapeutic Potential Against Haemophilus Parasuis in Pichia Pastoris.

Chimeric Fusion between <i>Clostridium Ramosum</i> IgA Protease and IgG Fc Provides Long-Lasting Clearance of IgA Deposits in Mouse Models of IgA Nephropathy

Development and Identification of Monoclonal Antibodies Against Porcine Reproductive and Respiratory Syndrome Virus

Development of a monoclonal antibody against PRRSV glycoprotein 3 using an immuodominant peptide as immunogen